Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

AMSTERDAM--(BUSINESS WIRE)--Nov 18, 2025--

Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/

The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio.

Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings together commercial excellence, scientific expertise, and deep functional capability across market access, pricing and reimbursement. This fully integrated approach enables biotech and pharma innovators to bring rare disease medicines to patients across all 32 European markets – an area where traditional go-to-market models often fail.

“We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite,” said Adam Plich, Founder and CEO of Avanzanite. “With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey,” concluded Plich.

In just three years, with three strategic alliances, Avanzanite has become the partner of choice for biotech and pharma innovators seeking to unlock the full European potential of their orphan medicines. Avanzanite’s current portfolio comprises three medicines across nephrology, ophthalmology and haematology with exclusive licensing or distribution rights in countries across the European Economic Area, the UK and Switzerland.

MVM is investing up to €32 million from its €500 million sixth fund. In addition, MVM has reserved significant capital to drive Avanzanite’s growth beyond the current round. MVM is Avanzanite’s first institutional investor and joins the company’s Board of Directors.

Dr. Jack Tanaka, Partner at MVM commented, “For years MVM has watched promising rare disease medicines struggle to find a path to patients - Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.”

About Avanzanite Bioscience

Avanzanite redefines launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, we partner with biotech and pharma innovators to unlock the full value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe’s complex landscape like master chess players – ensuring no patient is left behind while rewarding biotech and pharma innovators for their commitment to developing breakthrough therapies. For more information, visit www.avanzanite.com

About MVM Partners

MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston, London and the San Francisco Bay Area, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com

Jack Tanaka, MVM Partner.

Adam Plich, Founder and CEO of Avanzanite.

NEW YORK (AP) — Zuby Ejiofor had a career-high eight blocks along with 15 points and nine rebounds, anchoring a strong defensive performance that carried No. 23 St. John's past Mississippi 63-58 on Saturday night at Madison Square Garden.

Ejiofor scored all but two of his points in the second half, and the Red Storm (5-3) held on after leading by 14 with eight minutes remaining. He blocked six shots in the first half to go with three steals.

St. John's limited Ole Miss to 36.4% shooting from the field, including 2 for 16 from 3-point distance (12.5%), and forced 20 turnovers. The Johnnies went 25 of 35 on free throws to 16 of 20 for Mississippi and had a 13-0 advantage in fast-break points, enabling them to win despite shooting 34% from the floor and finishing with more turnovers (20) than field goals (17).

Malik Dia had 18 points and 10 rebounds in 27 minutes off the bench for the Rebels (5-4), who have lost four straight games — all to power-conference opponents. Dia started all 44 of his previous games at Ole Miss.

Ilias Kamardine scored 16 points for Mississippi, and Kezza Giffa added 10 points and seven steals off the bench.

AJ Storr, a 2023 All-Big East Freshman Team selection at St. John's, was booed throughout and scored only two points for Ole Miss. He missed all six of his field goal attempts.

Storr is playing for his fourth Power Five program in four years. He entered averaging 13.8 points per game, tied with Kamardine for the team lead.

The only previous meeting between the schools came on the St. John's campus in the first round of the 1989 National Invitation Tournament won by the Johnnies.

It was Mississippi's first game at The Garden since a 68-63 loss to Dayton in the semifinals of the 2010 NIT.

Mississippi plays Southern Miss next Saturday in Biloxi, Mississippi.

St. John's is back at MSG next Saturday to host local foe Iona, the suburban MAAC school where coach Rick Pitino spent three seasons before jumping to the Red Storm.

Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here and here (AP mobile app). AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball

St. John's forward Zuby Ejiofor (24) reacts after making a three-point basket against Auburn during the second half of an NCAA college basketball game in the Players Era tournament Wednesday, Nov. 26, 2025, in Las Vegas. (AP Photo/Steve Marcus)